(Q53061462)

11 May 2018

title

p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. (English)

1 reference

11 May 2018

1 reference

5

1 reference

11 May 2018

Robert A Soslow

7

1 reference

11 May 2018

author name string

Karuna Garg

1

1 reference

11 May 2018

Mario M Leitao

2

1 reference

11 May 2018

Christine A Wynveen

3

1 reference

11 May 2018

Gabriel L Sica

4

1 reference

11 May 2018

Weiji Shi

6

1 reference

11 May 2018

publication date

23 October 2009

1 reference

11 May 2018

published in

Modern Pathology

1 reference

11 May 2018

volume

23

1 reference

11 May 2018

issue

1

1 reference

11 May 2018

page(s)

80-92

1 reference

11 May 2018

https://scigraph.springernature.com/pub.10.1038/modpathol.2009.153

exact match

0 references

cites work

Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

Histologic and immunohistochemical decision-making in endometrial adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

Two pathogenetic types of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

Theories of endometrial carcinogenesis: a multidisciplinary approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

Uterine Endometrioid Carcinoma with Small Nonvillous Papillae: An Analysis of 26 Cases of a Favorable-Prognosis Tumor To Be Distinguished from Serous Carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

Clinical implications of the p53 tumor-suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

Uterine papillary serous carcinoma evolves via a p53-driven pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

p53 expression in neoplasms of the uterine corpus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

p16 expression in the female genital tract and its value in diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

MIB-1 in endometrial carcinoma: prognostic significance with 5-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

Endometrial Glandular Dysplasia with Frequent p53 Gene Mutation: A Genetic Evidence Supporting Its Precancer Nature for Endometrial Serous Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

TCL1A expression delineates biological and clinical variability in B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

Increased expression of mutant forms of p53 oncogene in primary lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

7 January 2021

Endometrioid endometrial adenocarcinoma with psammoma bodies

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

7 January 2021

Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

7 January 2021

The treatment of uterine papillary serous carcinoma (UPSC): are we doing the right thing?

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

7 January 2021

Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

7 January 2021

Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

7 January 2021

Stage IA uterine serous carcinoma: a study of 13 cases

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

7 January 2021

p53 expression as a prognostic indicator of 5-year survival in endometrial cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

7 January 2021

Uterine papillary serous carcinoma: patterns of metastatic spread

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

7 January 2021

Immunohistochemical analysis of p53 and HER-2/neu proteins in human tumors

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

7 January 2021

Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

7 January 2021

Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

7 January 2021

The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

7 January 2021

Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

7 January 2021

Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

7 January 2021

The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

7 January 2021

Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

7 January 2021

Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

7 January 2021

Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

7 January 2021

Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.153

7 January 2021

10.1038/MODPATHOL.2009.153

Identifiers

DOI

1 reference

11 May 2018

PubMed ID

19855378

1 reference

11 May 2018